Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
MVP Stock Overview
Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices.
Medical Developments International Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$2.66 |
52 Week High | AU$5.45 |
52 Week Low | AU$2.80 |
Beta | 1.21 |
1 Month Change | -25.49% |
3 Month Change | -26.32% |
1 Year Change | -46.69% |
3 Year Change | -49.81% |
5 Year Change | -43.52% |
Change since IPO | 454.17% |
Recent News & Updates
Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates
The latest analyst coverage could presage a bad day for Medical Developments International Limited ( ASX:MVP ), with...
Shareholder Returns
MVP | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | -6.7% | -3.7% | -1.2% |
1Y | -46.7% | -17.9% | -0.009% |
Return vs Industry: MVP underperformed the Australian Pharmaceuticals industry which returned -17.9% over the past year.
Return vs Market: MVP underperformed the Australian Market which returned -0% over the past year.
Price Volatility
MVP volatility | |
---|---|
MVP Average Weekly Movement | 11.5% |
Pharmaceuticals Industry Average Movement | 10.4% |
Market Average Movement | 9.3% |
10% most volatile stocks in AU Market | 16.3% |
10% least volatile stocks in AU Market | 4.2% |
Stable Share Price: MVP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: MVP's weekly volatility (12%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 68 | Brent MacGregor | https://medicaldev.com |
Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. The company operates through three segments: Pharmaceuticals, Medical Devices, and Veterinary Products. It offers asthma and COPD pressurized metered dose inhalers, as well as masks and peak flow meters for asthma management for use in home or in hospitals; Penthrox, a prescription only medicine for pain in trauma; and medical devices, such as CPR face shield key rings, CPR masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, OXI port carry and hand bags, resuscitation kits, oxygen therapy masks, and resuscitators.
Medical Developments International Fundamentals Summary
MVP fundamental statistics | |
---|---|
Market Cap | AU$199.65m |
Earnings (TTM) | -AU$18.81m |
Revenue (TTM) | AU$22.30m |
8.5x
P/S Ratio-10.1x
P/E RatioIs MVP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MVP income statement (TTM) | |
---|---|
Revenue | AU$22.30m |
Cost of Revenue | AU$7.37m |
Gross Profit | AU$14.93m |
Other Expenses | AU$33.73m |
Earnings | -AU$18.81m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | -0.26 |
Gross Margin | 66.95% |
Net Profit Margin | -84.35% |
Debt/Equity Ratio | 0% |
How did MVP perform over the long term?
See historical performance and comparisonFuture Growth
How is Medical Developments International forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
53.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MVP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MVP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MVP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MVP's revenue (43.1% per year) is forecast to grow faster than the Australian market (4.8% per year).
High Growth Revenue: MVP's revenue (43.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MVP is forecast to be unprofitable in 3 years.
Past Performance
How has Medical Developments International performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-85.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MVP is currently unprofitable.
Growing Profit Margin: MVP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MVP is unprofitable, and losses have increased over the past 5 years at a rate of 85.8% per year.
Accelerating Growth: Unable to compare MVP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MVP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.9%).
Return on Equity
High ROE: MVP has a negative Return on Equity (-30.33%), as it is currently unprofitable.
Financial Health
How is Medical Developments International's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MVP's short term assets (A$40.5M) exceed its short term liabilities (A$9.1M).
Long Term Liabilities: MVP's short term assets (A$40.5M) exceed its long term liabilities (A$24.9M).
Debt to Equity History and Analysis
Debt Level: MVP is debt free.
Reducing Debt: MVP has no debt compared to 5 years ago when its debt to equity ratio was 2.2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MVP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MVP has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 37.7% each year.
Dividend
What is Medical Developments International current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MVP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MVP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MVP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MVP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: MVP is not paying a notable dividend for the Australian market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MVP has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Brent MacGregor (57 yo)
1.5yrs
Tenure
AU$1,325,143
Compensation
Mr. Brent MacGregor serves as Director at Dynavax Technologies Corporation since July 2020. He has been the Chief Executive Officer of Medical Developments International Limited since November 01, 2020. Mr...
CEO Compensation Analysis
Compensation vs Market: Brent's total compensation ($USD936.76K) is above average for companies of similar size in the Australian market ($USD291.26K).
Compensation vs Earnings: Insufficient data to compare Brent's compensation with company performance.
Leadership Team
Experienced Management: MVP's management team is considered experienced (2.8 years average tenure).
Board Members
Experienced Board: MVP's board of directors are considered experienced (4.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Medical Developments International Limited's employee growth, exchange listings and data sources
Key Information
- Name: Medical Developments International Limited
- Ticker: MVP
- Exchange: ASX
- Founded: 2003
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$199.654m
- Shares outstanding: 71.31m
- Website: https://medicaldev.com
Number of Employees
Location
- Medical Developments International Limited
- 4 Caribbean Drive
- Scoresby
- Victoria
- 3179
- Australia
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/25 00:00 |
End of Day Share Price | 2022/05/25 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.